Drug Trial Radar · NCT06627751
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
May 1, 2027
Study completion May 1, 2030
Sponsor
- Lead sponsor
- Roswell Park Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \[EMD\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed/refractory multiple myeloma (RRMM) with EMD.
Conditions
- Extramedullary Disease in Multiple Myeloma
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
Interventions
MezigdomideBiological
Given PO
CarfilzomibDrug
Given IV
DexamethasoneDrug
Given PO
EchocardiographyProcedure
Undergo ECHO
Positron Emission TomographyProcedure
Undergo PET/CT
Computed TomographyProcedure
Undergo PET/CT
Computed Tomography Assisted BiopsyProcedure
Undergo CT guided tumor Biopsy
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration biopsy
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Biospecimen CollectionProcedure
Undergo blood and saliva sample collection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: At the end of cycle 6 (each cycle is 28 days).
- Clinical benefit rateTime frame: At the end of cycle 6 (each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.